Defence Therapeutics Secures NOL From Health Canada For Phase I Trial of AccuTOX
Defence Therapeutics Secures NOL From Health Canada For Phase I Trial of AccuTOX
Defence Therapeutics獲得加拿大衛生部的NOL,用於AccuTOX的I期臨床試驗。
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊